U.S. Wireless Telecom Stock News

Alibaba Group Holding (BABA) Q3 2026 earnings snapshot Alibaba Group Holding (BABA) just posted Q3 2026 results with revenue of ¥284.8b and basic EPS of ¥7.03, as investors weigh these numbers against a forecast calling for revenue growth of 9.1% per year and earnings growth of about 19.6% per year. The company has seen quarterly revenue move between ¥236.5b and ¥284.8b over the past six reported periods, while basic EPS has ranged from ¥5.36 to ¥21.07, set against trailing twelve month EPS...

Wondering whether SkyWest's current share price reflects its true value, or if the market is mispricing the stock. SkyWest recently closed at US$89.36, with a 0.2% decline over 7 days, a 16.8% decline over 30 days, an 11.7% decline year to date, a 1.1% decline over 1 year, a very large gain over 3 years and a 66.0% gain over 5 years, which may have caught your attention. Recent price moves sit against a backdrop where investors are reassessing airlines and regional carriers in light of...

If you are wondering whether York Space Systems at around US$17.68 offers value or just extra risk, the key is to separate short term noise from what the current price actually implies. The share price has recently been under pressure, with a 7 day return of 11.5% decline, a 30 day move of 36.9% decline, and a year to date return of 47.4% decline. This naturally raises questions about whether sentiment has swung too far. Recent news coverage has focused on York Space Systems as part of the...

The conflict in Iran that is limiting fertilizer shipments through the Strait of Hormuz has pushed nitrogen producers into focus, with CVR Partners (UAN) drawing attention as supply tightens and ammonia prices respond. See our latest analysis for CVR Partners. At a share price of $131.26, CVR Partners has seen a 30 day share price return of 22.67% and a 90 day share price return of 37.47%, while the 1 year total shareholder return of 93.50% reflects strong long term gains. This suggests that...

If you are wondering whether Brown & Brown is offering fair value at its current price, the stock’s mixed return profile and valuation checks provide a useful starting point. The share price last closed at US$66.56, with returns of a 1.6% decline over 7 days, a 3.3% decline over 30 days, a 14.2% decline year to date, a 44.0% decline over 1 year, but gains of 23.3% over 3 years and 50.0% over 5 years. Recent coverage around Brown & Brown has focused on its position within the insurance sector...

Wondering if Sonoco Products at around US$51.81 is offering fair value right now, or if the market is mispricing it? This article walks through the numbers so you can judge that for yourself. The stock shows mixed recent returns, with a 1 week return of a 1.8% decline, a 1 month return of an 8.7% decline, but a 16.8% gain year to date and 13.4% over the last year, which may catch your eye if you are tracking momentum and risk. Recent attention on packaging companies around input costs,...

If you are trying to work out whether Federal Home Loan Mortgage at US$4.41 is still attractively priced or now carrying more risk, the recent share moves give you plenty to think about. The stock has seen a 16.9% decline over the last 7 days and a 36.4% decline over the last 30 days, yet it still sits on a 137.1% return over 5 years and a very large return over 3 years that is above 10x. These sharp short term moves and the strong multi year performance have kept valuation in focus for...

In recent updates, Expand Energy outlined expectations for ongoing operational efficiencies in Fiscal 2026, including higher well productivity in the Haynesville formation and lower capital costs per foot across its natural gas and oil shale assets in Louisiana, Pennsylvania, West Virginia, and Ohio. This focus on productivity and cost discipline highlights how technology-driven improvements in core shale regions may increasingly shape the company’s operational profile and capital allocation...

In March 2026, Erasca, Inc. reported a full-year 2025 net loss of US$124.55 million, with basic loss per share from continuing operations of US$0.44, both improving versus the prior year. Earlier that month, Erasca exercised its option to expand its license with Joyo Pharmatech, securing exclusive global rights to the potential pan-RAS molecular glue ERAS-0015 and enabling a single worldwide development and commercialization plan. With Erasca now holding worldwide rights to ERAS-0015, we’ll...

CytomX Therapeutics recently reported full-year 2025 results showing sales of US$76.2 million and a net loss of US$17.37 million, and has just raised roughly US$250.00 million through a follow-on offering of common stock and pre-funded warrants at about US$5.30 per security. At the same time, the company released encouraging Phase 1 data for its EpCAM-targeted ADC Varseta-M in heavily pretreated metastatic colorectal cancer, with a high disease control rate and a safety profile that appears...

Titan America (NYSE:TTAM) has agreed to acquire Keystone Cement, expanding its presence and capacity in the Mid-Atlantic region. The company reports record revenue, EBITDA and operating cash flows for 2025, despite sector headwinds. These developments have not yet been widely discussed and may reshape Titan America's growth profile and operational footprint. For investors tracking NYSE:TTAM, the stock last closed at $14.71, with a 1 year return of 15.1% and a 12.0% decline year to date...

Callaway Golf stock in focus after name change Callaway Golf (CALY) is back in the spotlight after reverting to its historic name in January 2026, following a period as Topgolf Callaway Brands Corp. The move is drawing fresh attention to its core golf equipment and apparel business. See our latest analysis for Callaway Golf. The recent name change headlines arrive as momentum rebuilds, with a 16.9% year to date share price return and a 107.3% 1 year total shareholder return contrasting with...

Why Protalix BioTherapeutics is Back on Investors’ Radar Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone. See our latest analysis for Protalix BioTherapeutics. The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...

H&R Block (NYSE:HRB) has been named Best Overall Tax Service for 2026. The company also received recognition for Best Use of AI for 2026. These awards highlight H&R Block's AI Tax Assist and Sidekick AI tools in client and professional tax preparation. H&R Block, trading at $30.88, now carries recent recognition as both Best Overall Tax Service and Best Use of AI for 2026, which directly ties to its core tax preparation business. Over 5 years, NYSE:HRB has a return of 77.6%, while the 1...

This article examines whether Patterson-UTI Energy is attractively priced or already fully valued by focusing on what the current share price may be implying. The stock last closed at US$10.72, with returns of 8.8% over 7 days, 35.4% over 30 days, 65.7% year to date, 34.6% over 1 year, 12.6% over 3 years and 67.0% over 5 years. These figures may signal shifting views on its prospects and risk. Recent coverage has highlighted Patterson-UTI Energy as an energy services provider. This includes...

If you are wondering whether WisdomTree at US$13.86 still offers value after a strong run, a useful starting point is to understand how its current price lines up against different valuation measures. The stock has pulled back 8.5% over the past week and 16.3% over the past month. Even so, it is still up 10.8% year to date and 59.4% over the last year, as well as a very large gain over five years of 153.4%. Recent news flow around WisdomTree has focused on its position within the broader...

For investors considering whether Vornado Realty Trust at around US$26.48 reflects enough potential or already embeds too much optimism, this article breaks down what the current share price really represents. The stock has had a mixed run, with a 1.7% gain over the last 7 days, an 8.8% decline over the last 30 days, a 20.8% decline year to date, a 29.9% decline over 1 year, and a 114.6% return over 3 years, compared with a 32.1% decline over 5 years. Recent coverage around Vornado Realty...

On March 11, 2026, NCR Atleos Corporation announced that holders of a majority of its 9.500% Senior Secured Notes due 2029 consented to amendments to the governing indenture, enabling the company, its guarantor subsidiaries, and the trustee to execute a binding supplemental indenture effective immediately. This successful consent solicitation comes shortly after NCR Atleos reported quarterly results with revenue in line with expectations but earnings ahead of forecasts, highlighting the...

Wondering whether THOR Industries at around US$76 a share is a bargain or a value trap? This article walks through the numbers so you can judge whether the current price lines up with the fundamentals. The stock has seen a 7.3% decline over the past week, a 33.5% decline over the past month, and is down 27.6% year to date, while the 1-year return sits at a 2.7% decline. These moves have kept THOR Industries on many watchlists, with investors reacting to ongoing headlines around the broader...

Cabot’s recent share performance and business snapshot Cabot (CBT) has seen mixed share performance recently, with a modest 1 day gain, a slight 7 day pullback, and a larger decline over the past month, alongside a positive return over the past 3 months. The specialty chemicals group, headquartered in Boston, reports annual revenue of US$3,607.0 million and net income of US$306.0 million. Its operations span Reinforcement Materials, Performance Chemicals, and smaller unallocated...

Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing. See our latest analysis for Ovid Therapeutics. The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...

Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS. The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. The transaction is described as immediately accretive to adjusted EBITDA. For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...

If you are wondering whether AECOM’s current share price really reflects what you are getting for your money, this article breaks down the key numbers so you can judge the value for yourself. The stock most recently closed at US$90.32, with returns of 0.6% over 7 days, a 1.0% decline over 30 days, a 6.3% decline year to date, and a 3.9% decline over the last year. Over a longer horizon, AECOM has delivered total returns of 15.0% over 3 years and 49.3% over 5 years, which gives important...

If you are wondering whether NBT Bancorp at around US$40.97 is starting to look interesting, the current share price and fundamentals raise some clear valuation questions worth unpacking. The stock has seen a 0.7% decline over the last week, a 10.4% decline over the past month, and a 1.5% decline year to date, while the 1 year, 3 year, and 5 year returns stand at a 1.9% decline, 34.7%, and 21.3% respectively. Recent attention on regional banks, regulatory capital expectations, and investor...